Travere Therapeutics (NASDAQ:TVTX) posted a profit for the first quarter on Monday.
The company reported quarterly earnings of 5 cents per share which beat the analyst consensus estimate of losses of 26 cents per share. The company reported quarterly sales of $127.199 million which missed the analyst consensus estimate of $136.822 million.
“This has been a transformative start to the year for Travere, highlighted by the landmark approval of FILSPARI in FSGS, record demand that reinforces FILSPARI’s foundational position in IgAN, and the advancement of pegtibatinase with the first new patient dosed in the restarted Phase 3 HARMONY study,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “With FILSPARI now positioned to help more than 100,000 …
This post was originally published here
